Drugs / CELZ-201-DDT
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06053242 | May 2024 → May 2026 overdue | chronic pain syndrome, intervertebral disk degenerative disorder | Creative Medical Technology Holdings Inc | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07137559 | — | chronic pain syndrome, lumbar disk degenerative disorder | Creative Medical Technology Holdings Inc | Available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CELZ-201-DDT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07137559 ↗ |
| Modality | Cell therapy | “6x10\^6 cells” NCT06053242 ↗ |
| Route | Intramuscular | “paraspinal intramuscular injection” NCT06053242 ↗ |